

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/001130

International filing date: 18 March 2005 (18.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0406125.5
Filing date: 18 March 2004 (18.03.2004)

Date of receipt at the International Bureau: 24 May 2005 (24.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB2005/001130
The Patent Office
PATENTS • DESIGNS •
COPYRIGHT • TRADE MARKS




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Garside*
Dated 9 May 2005



19MAR04 E882129-15 D00060
P01/7700 0.00-0406125.5 CHEQUE**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

**The Patent Office**Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

RJW/CP6214761

2. Patent application number

(The Patent Office will fill this part in)

0406125.5

18 MAR 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD.
The Old Schools
Trinity Lane
CAMBRIDGE CB2 1TN

Patents ADP number (if you know it)

8206484007

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND

4. Title of the invention

METHODS OF AMINATION

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS *U*
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application
Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

YES

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description	34	8
Claim(s)	3	
Abstract		
Drawing(s)		

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

/

Request for a preliminary examination and search (Patents Form 9/77)

1

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Mervin Ellis

Date 18 March 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

ROBERT WATSON
020 7240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Methods of Amination

The present invention relates to methods of amination, and in particular to methods of aminating aromatic groups using
5 transition metal catalysis.

Amine derivatives are exceptionally important pharmaceutical intermediates and active ingredients in many drugs. Aromatic amines form the basis of the modern organic-based
10 photoconductors in xerography (photocopiers and photoconductors) [References 1-4], solar cells and as hole transporting materials in organic and polymeric light emitting devices [References 5-11].

15 Supercritical carbon dioxide and compressed carbon dioxide have emerged as a general environmentally benign solvent for the synthesis of organic molecules [References 12 and 13] and polymers [Reference 14]. It can be particularly beneficial in a variety of palladium-mediated syntheses and cross coupling
20 reactions [References 15-18] and for the integration of synthesis with processing. Particular examples of use in organic electronic materials are described by Ober and DeSimone [References 19-22]. Opportunities for the controlled deposition of organic and polymeric electronic materials have been
25 disclosed [Reference 23]. Deposition from compressed CO₂ will allow the controlled supramolecular ordering of materials owing to the ability to control demixing of samples during deposition from CO₂ solutions.

30 Amination reactions have been historically developed using the Ullmann coupling procedure [References 24 to 27], which involves the copper-mediated coupling of aryl halides and aryl 4-toluenesulfonates. More recently a family of palladium catalysed aromatic amination reactions have been developed in
35 which an aryl halide or aryl tosylate is typically coupled with an amine derivative in the presence of a palladium (0) catalyst,

a suitable bulky organophosphine ligand and a base [Reference 28]. The scope and methodology of such a procedure (the 'Buchwald-Hartwig' amination reaction) has been reviewed by Buchwald and Hartwig [References 29-31] and forms the basis of a wide variety of amine syntheses. The use of these methods for the manufacture of electroactive polymers has been described [Reference 32].


There is an attraction in combining the synthesis of aminederivatives and the subsequent processing in compressed CO₂. Advantages could include an environmentally friendly manufacturing process plus control of morphology of the final product using anti-solvent techniques (see A. I. Cooper's review [Reference 14]) for pharmaceuticals. In the electroactive organic and polymeric materials arena an advantage of integrated synthesis and processing will lead to architecturally controlled multilayered devices with supramolecular order. A particular example is the use of blended materials to improve organic LED device performance [Reference 33]. Another example of the benefit of an integrated synthesis and processing system is the advantage of polymer deposition where layer separation is required, by virtue of the immiscibility of the deposition solvent with the first layer, or induction of microphase segregation of two materials co-deposited from carbon dioxide whose solubility difference can be exploited to generate organised and phase segregated materials. This feature has specific advantages in organic photovoltaic devices [Reference 34].

Although palladium catalysed carbon-carbon bond formation reactions in supercritical CO₂ have been described [Reference 36], prior art in the field would suggest that carrying out the palladium catalysed amination reaction in compressed CO₂ (the Buchwald-Hartwig amination reaction) would fail because it is well known that amines form carbamic acids in the presence of carbon dioxide. In fact, the formation of a carbamic acid has

been used to suppress the reactivity of a free amino substituent in the course of a synthesis in compressed carbon dioxide [Reference 35].

5 The present inventors have now discovered that palladium catalysed amination reactions can be carried in compressed CO₂ by the use of selected N-silylamines.


10 Accordingly, the present invention provides a method of synthesising a compound of formula I:



comprising the step of reacting a moiety of formula II:



with a moiety of formula III:



15

in compressed carbon dioxide in the presence of a transition metal catalyst and a base, wherein:

L is a labile leaving group;

R^{N1} is optionally substituted C₅₋₂₀ aryl;

20 R^{N2} is selected from optionally substituted C₅₋₂₀ aryl, optionally substituted C₃₋₂₀ heterocyclyl, optionally substituted C₃₋₇ alkyl, and optionally substituted sulfonyl;

R^{N3} is selected from H and optionally substituted C₁₋₇ alkyl, C₃₋₂₀ heterocyclyl and C₅₋₂₀ aryl; or

25 R^{N2} and R^{N3} together with the nitrogen atom to which they are attached form optionally substituted nitrogen-containing C₃₋₂₀ heterocyclyl or C₅₋₂₀ heteroaryl; and

R¹, R² and R³ are independently selected from optionally substituted C₁₋₇ alkyl, C₅₋₂₀ aryl, C₃₋₂₀ heterocyclyl, hydroxy,

30 halo, amino and C₁₋₇ alkoxy, or two of R¹, R² and R³, together with the silicon atom to which they are attached, may form a silicon containing C₅₋₇ heterocyclyl group (e.g. silacyclobutyl).

R^{N1} and R^{N2} may be linked by a single bond, such that the compound of formula I comprises a nitrogen-containing C₅₋₇ heterocyclyl or heteroaryl group formed from R^{N1} and R^{N2}, and the nitrogen to which they are attached.

It has also been found that these reactions proceed more efficiently than when carried out in an organic solvent, such as toluene.

10

Compressed carbon dioxide

The term "compressed carbon dioxide" means herein carbon dioxide which has been compressed under pressure to produce liquid carbon dioxide or supercritical or near supercritical carbon dioxide.

15

A fluid is termed "supercritical" when its temperature exceeds the critical temperature (Tc). At this point the two fluid phases, liquid and vapor, become indistinguishable [Reference 20 37]. The critical temperature of carbon dioxide is 31.1°C and the critical pressure 73.8 bar. Conditions and solvent media required to form supercritical or near supercritical states are described in Reference 12 and References 38 to 45.

25

The reaction is preferably carried out at a pressure between 800psi and 4000psi. More preferably the reaction pressure is greater than, or equal to, 1500 psi. The reaction is also more preferably less than, or equal to, 3500 psi.

30

Transition metal catalyst

Suitable transition metal catalysts include complexes of platinum, palladium, iron, nickel, ruthenium and rhodium. Catalyst complexes may include chelating ligands, such as, by way of example only, C₁₋₇ alkyl and C₅₋₂₀ aryl derivatives of phosphines and bisphosphines, imines, arsines and hybrids thereof, including hybrids of phosphines with amines.

35

Additionally, heterogeneous catalysts containing forms of these elements are also suitable as catalysts for the present invention. Catalysts containing palladium and copper are preferred, with palladium based catalysts being more preferred.

The active form of the transition metal catalyst is not well characterised. Therefore, the term "transition metal catalyst" as used herein refers to any transition metal catalyst and/or catalyst precursor as is introduced into the reaction vessel and which is, if necessary, converted into the active phase, as well as active form, of the catalyst which participates in the reaction.

The palladium catalysts most suitable for use in the present invention are formed from palladium(II) salts and appropriate ligands, preferably phosphine ligands. Such catalysts are known in the art and are described in Reference 12, 36, 38-45. Particularly preferred catalysts include Pd catalysts with one or more phosphine ligands such as PPh_3 , $\text{P}(\text{C}_6\text{H}_{12})_3$, 2-diphenylphosphinophenol, binap, dppf, $\text{P}(\text{t-Bu})_2(\text{biphen})$ where biphen represents 2-phenyl-phen-1-yl, where the 2-phenyl group may bear at one or more of the 2', 4' and 6'- positions iso-propyl groups or *N,N*-dimethyl amino groups. Examples of catalysts include, but are not limited to, those derived from Pd(II) acetate (especially with $\text{P}(\text{t-Bu})_2(\text{biphen})$ ligands, where biphen is as defined above), $\text{Pd}(\text{PPh}_3)_4$, $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ and $\text{Pd}(\text{dppf})\text{Cl}_2$.

Other preferred transition metal (preferably palladium) catalysts are those based on the *N*-heterocyclic carbenoid ligands described for example by Nolan [Reference 46], and the micro-encapsulated transition metal catalysts disclosed in Reference 36.

The transition metal catalyst is preferably present in the range of 0.001 to 20 mol%, and preferably 1.0 to 2.5 or 5 mol%, with respect to the moiety of formula II.

5 *Base*

Suitable bases for use in the present invention include bases of group 1 metals, carbonate, phosphate or tert-butoxy/phenoxy bases and superbases [References 47 and 48]. Preferred bases are group 1 metal carbonate, phosphate or tert-butoxy/phenoxy bases, such as K_2CO_3 , K_3PO_4 , Na_2CO_3 , Cs_2CO_3 , $K(t\text{-}BuO)$, $Na(t\text{-}BuO)$, $K(OPh)$, $Na(OPh)$, and tetraalkylammonium salts or mixtures thereof.

15 Preferred bases include K_2CO_3 , Na_2CO_3 and Cs_2CO_3 , of which Cs_2CO_3 is most preferred.

The base is preferably present as 1 to 4 equivalents of the moiety of formula II, and more preferably as 1 to 1.5 or 2 equivalents.

20

Optional Additive

The reaction mixture may also contain an optional additive which acts as a fluoride source, to aid the progress of the reaction. Such fluoride sources include, but are not limited to, KF , CsF ,
25 tetrabutylammonium fluoride, tris(diethylaminosulfonylum difluorotrimethylsilicate (TASF) and tetrabutylammonium triphenyldifluorosilicate (TBAT), of which KF is most preferred.

30 The optional additive is preferably present as 1 to 2 equivalents of the moiety of formula III, and more preferably as 1 to 1.3 or 1.5 equivalents.

Labile leaving group

35 Labile leaving groups suitable for use in the present invention are in particular those known to be amenable to palladium catalysed coupling. Suitable groups include mesylate ($-\text{OSO}_2\text{CH}_3$);

-OSO₂(C_nF_{2n+1}), where n=0-4; -OSO₂-R^s, where R^s is an optionally substituted phenyl group (e.g. 4-Me-Ph, tosylate); -N^tMe₃X⁻, where X may be OTf, OTs, I, Br, Cl, OH; I, Br and Cl. More preferred are -OSO₂(C_nF_{2n+1}) where n=0,1 or 4 (in particular triflate), I, Br and Cl, with Br being the most preferred.

5 *Amount of compound of formula III*

When the moiety of formula III is not bound to the moiety of formula II, it is preferably present as 1 to 2 equivalents, and 10 is more preferably 1 to 1.3 or 1.5 equivalents, of the compound of formula II.

15 *Reaction Temperature*

The reaction is preferably carried out at room temperature (i.e. 20°C) or higher, more preferably higher than 50°C, but at 200°C or lower. A most preferred temperature range for the reaction is between 60°C and 120°C, with temperatures of about 100°C being particularly preferred.

20 *Substituents*

The phrase "optionally substituted" as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.

25 Unless otherwise specified, the term "substituted" as used herein, pertains to a parent group which bears one or more substituents. The term "substituent" is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent 30 group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known.

Examples of substituents are described in more detail below.

C₁₋₇ alkyl: The term "C₁₋₇ alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.

Examples of saturated alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), propyl (C₃), butyl (C₄), pentyl (C₅), hexyl (C₆) and heptyl (C₇).

Examples of saturated linear alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄), n-pentyl (amyl) (C₅), n-hexyl (C₆) and n-heptyl (C₇).

Examples of saturated branched alkyl groups include iso-propyl (C₃), iso-butyl (C₄), sec-butyl (C₄), tert-butyl (C₄), iso-pentyl (C₅), and neo-pentyl (C₅).

C₂₋₇ Alkenyl: The term "C₂₋₇ alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.

Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH₂), 1-propenyl (-CH=CH-CH₃), 2-propenyl (allyl, -CH-CH=CH₂), isopropenyl (1-methylvinyl, -C(CH₃)=CH₂), butenyl (C₄), pentenyl (C₅), and hexenyl (C₆).

C₂₋₇ alkynyl: The term "C₂₋₁₂ alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.

Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C≡CH) and 2-propynyl (propargyl, -CH₂-C≡CH).

C₃₋₇ cycloalkyl: The term "C₃₋₇ cycloalkyl" as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon

5 (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.

Examples of cycloalkyl groups include, but are not limited to, those derived from:

10 saturated monocyclic hydrocarbon compounds:

cyclopropane (C₃), cyclobutane (C₄), cyclopentane (C₅), cyclohexane (C₆), cycloheptane (C₇), methylcyclopropane (C₄), dimethylcyclopropane (C₅), methylcyclobutane (C₅), dimethylcyclobutane (C₆), methylcyclopentane (C₆),

15 dimethylcyclopentane (C₇) and methylcyclohexane (C₇);

unsaturated monocyclic hydrocarbon compounds:

cyclopropene (C₃), cyclobutene (C₄), cyclopentene (C₅), cyclohexene (C₆), methylcyclopropene (C₄), dimethylcyclopropene (C₅), methylcyclobutene (C₅), dimethylcyclobutene (C₆),

20 methylcyclopentene (C₆), dimethylcyclopentene (C₇) and methylcyclohexene (C₇); and

saturated polycyclic hydrocarbon compounds:

norcarane (C₇), norpinane (C₇), norbornane (C₇).

25 C₃₋₂₀ heterocyclyl: The term "C₃₋₂₀ heterocyclyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, 30 of which from 1 to 4 are ring heteroatoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₃₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term

35 "C₅₋₆heterocyclyl", as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.

Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N₁: aziridine (C₃), azetidine (C₄), pyrrolidine
5 (tetrahydropyrrole) (C₅), pyrroline (e.g., 3-pyrroline,
2,5-dihydropyrrole) (C₅), 2H-pyrrole or 3H-pyrrole (isopyrrole,
isoazole) (C₅), piperidine (C₆), dihydropyridine (C₆),
tetrahydropyridine (C₆), azepine (C₇);
O₁: oxirane (C₃), oxetane (C₄), oxolane (tetrahydrofuran) (C₅),
10 oxole (dihydrofuran) (C₅), oxane (tetrahydropyran) (C₆),
dihydropyran (C₆), pyran (C₆), oxepin (C₇);
S₁: thiirane (C₃), thietane (C₄), thiolane (tetrahydrothiophene)
(C₅), thiane (tetrahydrothiopyran) (C₆), thiepane (C₇);
O₂: dioxolane (C₅), dioxane (C₆), and dioxepane (C₇);
15 O₃: trioxane (C₆);
N₂: imidazolidine (C₅), pyrazolidine (diazolidine) (C₅),
imidazoline (C₅), pyrazoline (dihydropyrazole) (C₅), piperazine
(C₆);
N₁O₁: tetrahydrooxazole (C₅), dihydrooxazole (C₅),
20 tetrahydroisoxazole (C₅), dihydroisoxazole (C₅), morpholine (C₆),
tetrahydrooxazine (C₆), dihydrooxazine (C₆), oxazine (C₆);
N₁S₁: thiazoline (C₅), thiazolidine (C₅), thiomorpholine (C₆);
N₂O₁: oxadiazine (C₆);
O₁S₁: oxathiole (C₅) and oxathiane (thioxane) (C₆); and,
25 N₁O₁S₁: oxathiazine (C₆).

Examples of substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C₅), such as arabinofuranose, lyxofuranose,
30 ribofuranose, and xylofuranose, and pyranoses (C₆), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.

C₅₋₂₀ aryl: The term "C₅₋₂₀ aryl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has

from 3 to 20 ring atoms. Preferably, each ring has from 5 to 7 ring atoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₅₋₇, C₅₋₆, etc.) denote 5 the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆ aryl" as used herein, pertains to an aryl group having 5 or 6 ring atoms.

10 The ring atoms may be all carbon atoms, as in "carboaryl groups".

Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e. phenyl) (C₆), naphthalene (C₁₀), azulene (C₁₀), anthracene (C₁₄), phenanthrene (C₁₄), naphthacene 15 (C₁₈), and pyrene (C₁₆).

Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1H-indene) (C₉), 20 indene (C₉), isoindene (C₉), tetrалine (1,2,3,4-tetrahydronaphthalene (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), and aceanthrene (C₁₆).

25 Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:

N₁: pyrrole (azole) (C₅), pyridine (azine) (C₆);

30 O₁: furan (oxole) (C₅);

S₁: thiophene (thiole) (C₅);

N₁O₁: oxazole (C₅), isoxazole (C₅), isoxazine (C₆);

N₂O₁: oxadiazole (furazan) (C₅);

N₃O₁: oxatriazole (C₅);

35 N₁S₁: thiazole (C₅), isothiazole (C₅);

N₂: imidazole (1,3-diazole) (C₅), pyrazole (1,2-diazole) (C₅),
pyridazine (1,2-diazine) (C₆), pyrimidine (1,3-diazine) (C₆)
(e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C₆);

N₃: triazole (C₅), triazine (C₆); and,

5 N₄: tetrazole (C₅).

Examples of heteroaryl which comprise fused rings, include, but
are not limited to:

C₉ (with 2 fused rings) derived from benzofuran (O₁),
10 isobenzofuran (O₁), indole (N₁), isoindole (N₁), indolizine (N₁),
indoline (N₁), isoindoline (N₁), purine (N₄) (e.g., adenine,
guanine), benzimidazole (N₂), indazole (N₂), benzoxazole (N₁O₁),
benzisoxazole (N₁O₁), benzodioxole (O₂), benzofurazan (N₂O₁),
benzotriazole (N₃), benzothiofuran (S₁), benzothiazole (N₁S₁),
15 benzothiadiazole (N₂S);

C₁₀ (with 2 fused rings) derived from chromene (O₁),
isochromene (O₁), chroman (O₁), isochroman (O₁), benzodioxan
(O₂), quinoline (N₁), isoquinoline (N₁), quinolizine (N₁),
benzoxazine (N₁O₁), benzodiazine (N₂), pyridopyridine (N₂),
20 quinoxaline (N₂), quinazoline (N₂), cinnoline (N₂), phthalazine
(N₂), naphthyridine (N₂), pteridine (N₄);

C₁₁ (with 2 fused rings) derived from benzodiazepine (N₂);

C₁₃ (with 3 fused rings) derived from carbazole (N₁),
dibenzofuran (O₁), dibenzothiophene (S₁), carboline (N₂),
25 perimidine (N₂), pyridoindole (N₂); and,

C₁₄ (with 3 fused rings) derived from acridine (N₁),
xanthene (O₁), thioxanthene (S₁), oxanthrene (O₂), phenoxathiin
(O₁S₁), phenazine (N₂), phenoxazine (N₁O₁), phenothiazine (N₁S₁),
thianthrene (S₂), phenanthridine (N₁), phenanthroline (N₂),

30 phenazine (N₂).

The above groups, whether alone or part of another substituent,
may themselves optionally be substituted with one or more groups
selected from themselves and the additional substituents listed

35 below.

Halo: -F, -Cl, -Br, and -I.

Hydroxy: -OH.

5 Ether: -OR, wherein R is an ether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇ alkoxy group, discussed below), a C₃₋₂₀ heterocyclyl group (also referred to as a C₃₋₂₀ heterocyclyloxy group), or a C₅₋₂₀ aryl group (also referred to as a C₅₋₂₀ aryloxy group), preferably a C₁₋₇alkyl group.

10 Alkoxy: -OR, wherein R is an alkyl group, for example, a C₁₋₇ alkyl group. Examples of C₁₋₇ alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), 15 -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

20 Acetal: -CH(OR¹)(OR²), wherein R¹ and R² are independently acetal substituents, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group, or, in the case of a "cyclic" acetal group, R¹ and R², taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, -CH(OMe)₂, -CH(OEt)₂, and 25 -CH(OMe)(OEt).

30 Hemiacetal: -CH(OH)(OR¹), wherein R¹ is a hemiacetal substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and -CH(OH)(OEt).

35 Ketal: -CR(OR¹)(OR²), where R¹ and R² are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples ketal groups include,

but are not limited to, $-\text{C}(\text{Me})(\text{OMe})_2$, $-\text{C}(\text{Me})(\text{OEt})_2$, $-\text{C}(\text{Me})(\text{OMe})(\text{OEt})$, $-\text{C}(\text{Et})(\text{OMe})_2$, $-\text{C}(\text{Et})(\text{OEt})_2$, and $-\text{C}(\text{Et})(\text{OMe})(\text{OEt})$.

5 Hemiketal: $-\text{CR(OH)(OR}^1)$, where R^1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to,

10 $-\text{C}(\text{Me})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Et})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Me})(\text{OH})(\text{OEt})$, and $-\text{C}(\text{Et})(\text{OH})(\text{OEt})$.

Oxo (keto, -one): $=\text{O}$.

15 Thione (thioketone): $=\text{S}$.

Imino (imine): $=\text{NR}$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group.

20 Examples of ester groups include, but are not limited to, $=\text{NH}$, $=\text{NMe}$, $=\text{NET}$, and $=\text{NPh}$.

Formyl (carbaldehyde, carboxaldehyde): $-\text{C}(=\text{O})\text{H}$.

25 Acyl (keto): $-\text{C}(=\text{O})\text{R}$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20} arylacyl), preferably a C_{1-7} alkyl group. Examples of acyl groups include, but are not limited to, $-\text{C}(=\text{O})\text{CH}_3$ (acetyl), $-\text{C}(=\text{O})\text{CH}_2\text{CH}_3$ (propionyl), $-\text{C}(=\text{O})\text{C}(\text{CH}_3)_3$ (t-butyryl), and $-\text{C}(=\text{O})\text{Ph}$ (benzoyl, phenone).

Carboxy (carboxylic acid): $-\text{C}(=\text{O})\text{OH}$.

35

Thiocarboxy (thiocarboxylic acid): $-\text{C}(=\text{S})\text{SH}$.

Thiolocarboxy (thiolocarboxylic acid): $-C(=O)SH$.

Thionocarboxy (thionocarboxylic acid): $-C(=S)OH$.

5

Imidic acid: $-C(=NH)OH$.

Hydroxamic acid: $-C(=NOH)OH$.

10 Ester (carboxylate, carboxylic acid ester, oxycarbonyl):
 $-C(=O)OR$, wherein R is an ester substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of ester groups include, but are not limited to, $-C(=O)OCH_3$, $-C(=O)OCH_2CH_3$, $-C(=O)OC(CH_3)_3$,
15 and $-C(=O)OPh$.

Acyloxy (reverse ester): $-OC(=O)R$, wherein R is an acyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group.

20 Examples of acyloxy groups include, but are not limited to,
 $-OC(=O)CH_3$ (acetoxy), $-OC(=O)CH_2CH_3$, $-OC(=O)C(CH_3)_3$, $-OC(=O)Ph$, and $-OC(=O)CH_2Ph$.

25 Oxycarboxyloxy: $-OC(=O)OR$, wherein R is an ester substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of ester groups include, but are not limited to, $-OC(=O)OCH_3$, $-OC(=O)OCH_2CH_3$, $-OC(=O)OC(CH_3)_3$, and $-OC(=O)OPh$.

30 Amino: $-NR^1R^2$, wherein R¹ and R² are independently amino substituents, for example, hydrogen, a C₁₋₇ alkyl group (also referred to as C₁₋₇ alkylamino or di-C₁₋₇ alkylamino), a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇ alkyl group, or, in the case of a "cyclic" amino group, R¹ and R², taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring

atoms. Amino groups may be primary ($-\text{NH}_2$), secondary ($-\text{NHR}^1$), or tertiary ($-\text{NHR}^1\text{R}^2$), and in cationic form, may be quaternary ($-\text{NR}^1\text{R}^2\text{R}^3$). Examples of amino groups include, but are not limited to, $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{NHC}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_2\text{CH}_3)_2$, and $-\text{NHPh}$.


5 Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.

Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide):

10 $-\text{C}(=\text{O})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{NHCH}_3$, $-\text{C}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{C}(=\text{O})\text{NHCH}_2\text{CH}_3$, and $-\text{C}(=\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, as well as amido groups in which R^1 and R^2 , together with the nitrogen atom 15 to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.

20 Thioamido (thiocarbamyl): $-\text{C}(=\text{S})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-\text{C}(=\text{S})\text{NH}_2$, $-\text{C}(=\text{S})\text{NHCH}_3$, $-\text{C}(=\text{S})\text{N}(\text{CH}_3)_2$, and $-\text{C}(=\text{S})\text{NHCH}_2\text{CH}_3$.

25 Acylamido (acylamino): $-\text{NR}^1\text{C}(=\text{O})\text{R}^2$, wherein R^1 is an amide substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group, and R^2 is an acyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of acylamide groups include, but are not limited to, $-\text{NHC}(=\text{O})\text{CH}_3$, $-\text{NHC}(=\text{O})\text{CH}_2\text{CH}_3$, and $-\text{NHC}(=\text{O})\text{Ph}$. R^1 and R^2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:




Aminocarbonyloxy: $-\text{OC}(=\text{O})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups.

5 Examples of aminocarbonyloxy groups include, but are not limited to, $-\text{OC}(=\text{O})\text{NH}_2$, $-\text{OC}(=\text{O})\text{NHMe}$, $-\text{OC}(=\text{O})\text{NMe}_2$, and $-\text{OC}(=\text{O})\text{NET}_2$.

Ureido: $-\text{N}(\text{R}^1)\text{CONR}^2\text{R}^3$ wherein R^2 and R^3 are independently amino substituents, as defined for amino groups, and R^1 is a ureido substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ureido groups include, but are not limited to, $-\text{NHCONH}_2$, $-\text{NHCONHMe}$, $-\text{NHCONHET}$, $-\text{NHCONMe}_2$, $-\text{NHCONET}_2$, $-\text{NMeCONH}_2$, $-\text{NMeCONHMe}$, $-\text{NMeCONHET}$, $-\text{NMeCONMe}_2$, and $-\text{NMeCONET}_2$.

Guanidino: $-\text{NH}-\text{C}(=\text{NH})\text{NH}_2$.

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,



Imino: $=\text{NR}$, wherein R is an imino substituent, for example, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of imino groups include, but are not limited to, $=\text{NH}$, $=\text{NMe}$, and $=\text{NET}$.

30 Amidine (amidino): $-\text{C}(=\text{NR})\text{NR}_2$, wherein each R is an amidine substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20}

heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇ alkyl group. Examples of amidine groups include, but are not limited to, -C(=NH)NH₂, -C(=NH)NMe₂, and -C(=NMe)NMe₂.

5 Nitro: -NO₂.

Nitroso: -NO.

Azido: -N₃.

10 Cyano (nitrile, carbonitrile): -CN.

Isocyano: -NC.

15 Cyanato: -OCN.

Isocyanato: -NCO.

Thiocyanato (thiocyanato): -SCN.

20 Isothiocyanato (isothiocyanato): -NCS.

Sulphydryl (thiol, mercapto): -SH.

25 Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇alkylthio group), a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of C₁₋₇ alkylthio groups include, but are not limited to, -SCH₃ and -SCH₂CH₃.

30 Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group (also referred to herein as C₁₋₇ alkyl disulfide). Examples of C₁₋₇ alkyl disulfide groups include, but are not limited to, -SSCH₃ and -SSCH₂CH₃.

Sulfine (sulfinyl, sulfoxide): $-S(=O)R$, wherein R is a sulfine substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group.

Examples of sulfine groups include, but are not limited to,

5 $-S(=O)CH_3$ and $-S(=O)CH_2CH_3$.

Sulfone (sulfonyl): $-S(=O)_2R$, wherein R is a sulfone substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group,

10 including, for example, a fluorinated or perfluorinated C₁₋₇ alkyl group. Examples of sulfone groups include, but are not limited to, $-S(=O)_2CH_3$ (methanesulfonyl, mesyl), $-S(=O)_2CF_3$ (triflyl), $-S(=O)_2CH_2CH_3$ (esyl), $-S(=O)_2C_4F_9$ (nonaflyl), $-S(=O)_2CH_2CF_3$ (tresyl), $-S(=O)_2CH_2CH_2NH_2$ (tauryl), $-S(=O)_2Ph$ (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).

20 Sulfinic acid (sulfino): $-S(=O)OH$, $-SO_2H$.

Sulfonic acid (sulfo): $-S(=O)_2OH$, $-SO_3H$.

Sulfinate (sulfinic acid ester): $-S(=O)OR$; wherein R is a

25 sulfinate substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfinate groups include, but are not limited to, $-S(=O)OCH_3$ (methoxysulfinyl; methyl sulfinate) and $-S(=O)OCH_2CH_3$ (ethoxysulfinyl; ethyl sulfinate).

30 Sulfonate (sulfonic acid ester): $-S(=O)_2OR$, wherein R is a sulfonate substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfonate groups include, but are not limited to, $-S(=O)_2OCH_3$ (methoxysulfonyl; methyl sulfonate) and $-S(=O)_2OCH_2CH_3$ (ethoxysulfonyl; ethyl sulfonate).

Sulfinyloxy: $-OS(=O)R$, wherein R is a sulfinyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of 5 sulfinyloxy groups include, but are not limited to, $-OS(=O)CH_3$ and $-OS(=O)CH_2CH_3$.

Sulfonyloxy: $-OS(=O)_2R$, wherein R is a sulfonyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a 10 C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfonyloxy groups include, but are not limited to, $-OS(=O)_2CH_3$ (mesylate) and $-OS(=O)_2CH_2CH_3$ (esylate).

Sulfate: $-OS(=O)_2OR$; wherein R is a sulfate substituent, for 15 example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfate groups include, but are not limited to, $-OS(=O)_2OCH_3$ and $-SO(=O)_2OCH_2CH_3$.

20 Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): $-S(=O)NR^1R^2$, wherein R¹ and R² are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, $-S(=O)NH_2$, $-S(=O)NH(CH_3)$, $-S(=O)N(CH_3)_2$, $-S(=O)NH(CH_2CH_3)$, $-S(=O)N(CH_2CH_3)_2$, and $-S(=O)NHPH$.

25 Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): $-S(=O)_2NR^1R^2$, wherein R¹ and R² are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-S(=O)_2NH_2$, $-S(=O)_2NH(CH_3)$, $-S(=O)_2N(CH_3)_2$, $-S(=O)_2NH(CH_2CH_3)$, $-S(=O)_2N(CH_2CH_3)_2$, and $-S(=O)_2NHPH$.

30 Sulfamino: $-NR^1S(=O)_2OH$, wherein R¹ is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, 35 but are not limited to, $-NHS(=O)_2OH$ and $-N(CH_3)S(=O)_2OH$.

Sulfonamino: $-NR^1S(=O)_2R$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of 5 sulfonamino groups include, but are not limited to, $-NHS(=O)_2CH_3$ and $-N(CH_3)S(=O)_2C_6H_5$.

Sulfinamino: $-NR^1S(=O)R$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, 10 for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinamino groups include, but are not limited to, $-NHS(=O)CH_3$ and $-N(CH_3)S(=O)C_6H_5$.

15 Phosphino (phosphine): $-PR_2$, wherein R is a phosphino substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphino groups 20 include, but are not limited to, $-PH_2$, $-P(CH_3)_2$, $-P(CH_2CH_3)_2$, $-P(t-Bu)_2$, and $-P(Ph)_2$.

Phospho: $-P(=O)_2$.

25 Phosphinyl (phosphine oxide): $-P(=O)R_2$, wherein R is a phosphinyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group or a C_{5-20} aryl group. Examples of phosphinyl groups 30 include, but are not limited to, $-P(=O)(CH_3)_2$, $-P(=O)(CH_2CH_3)_2$, $-P(=O)(t-Bu)_2$, and $-P(=O)(Ph)_2$.

Phosphonic acid (phosphono): $-P(=O)(OH)_2$.

35 Phosphonate (phosphono ester): $-P(=O)(OR)_2$, where R is a phosphonate substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphonate

groups include, but are not limited to, $-P(=O)(OCH_3)_2$, $-P(=O)(OCH_2CH_3)_2$, $-P(=O)(O-t-Bu)_2$, and $-P(=O)(OPh)_2$.

Phosphoric acid (phosphonooxy): $-OP(=O)(OH)_2$.

5

Phosphate (phosphonooxy ester): $-OP(=O)(OR)_2$, where R is a phosphate substituent, for example, -H, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphate groups include, but are not limited to, $-OP(=O)(OCH_3)_2$, $-OP(=O)(OCH_2CH_3)_2$, $-OP(=O)(O-t-Bu)_2$, and $-OP(=O)(OPh)_2$.

Phosphorous acid: $-OP(OH)_2$.

15 Phosphite: $-OP(OR)_2$, where R is a phosphite substituent, for example, -H, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphite groups include, but are not limited to, $-OP(OCH_3)_2$, $-OP(OCH_2CH_3)_2$, $-OP(O-t-Bu)_2$, and $-OP(OPh)_2$.

Phosphoramidite: $-OP(OR^1)-NR^2_2$, where R¹ and R² are phosphoramidite substituents, for example, -H, a (optionally substituted) C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphoramidite groups include, but are not limited to, $-OP(OCH_2CH_3)-N(CH_3)_2$, $-OP(OCH_2CH_3)-N(i-Pr)_2$, and $-OP(OCH_2CH_2CN)-N(i-Pr)_2$.

30 Phosphoramidate: $-OP(=O)(OR^1)-NR^2_2$, where R¹ and R² are phosphoramidate substituents, for example, -H, a (optionally substituted) C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphoramidate groups include, but are not limited to, $-OP(=O)(OCH_2CH_3)-N(CH_3)_2$, $-OP(=O)(OCH_2CH_3)-N(i-Pr)_2$, and $-OP(=O)(OCH_2CH_2CN)-N(i-Pr)_2$.

Further substituent groups

Particular substituent groups of interest are ion-chelating groups of formula $[-(\text{CH}_2\text{CH}_2\text{O})_n\text{CH}_2\text{CH}_2\text{OCH}_3]$, $[-\text{O}(\text{CH}_2\text{CH}_2\text{O})_n\text{OCH}_3]$,

5 $[-(\text{CH}_2\text{CH}(\text{R}^A)\text{O})_n\text{CH}_2\text{CH}_2\text{OCH}_3]$ and $[-\text{O}(\text{CH}_2\text{CH}(\text{R}^A)\text{O})_n\text{OCH}_3]$, wherein n is an integer from 0 to 10, preferably 2 to 10, more preferably 2 to 4, and R^A is C_{1-10} alkyl, preferably C_{1-2} alkyl, and wherein the ion chelating groups comprise side chains in ologomeric or polymeric structures.

10

The ion chelating side chains are based on the repeat unit $[-\text{OCH}_2\text{CH}_2-]$. Side chain branching and/or the inclusion of $[-\text{OCH}_2\text{O}-]$ repeat-units, are advantageous to inhibit crystallisation after metal ion complexation. The side chains contain preferably 3 or more $[-\text{OCH}_2\text{CH}_2-]$ and most preferably 3 units terminating in OR^A ($\text{R}^A = \text{C}_{1-10}$ alkyl, e.g. methyl) containing 4 oxygen atoms for cation chelation. Crown ethers may also be designed accordingly. Other side chain designs may be made according to the specific need for cation binding.

15 20 Alternative design features could be incorporated into monomers and polymers to favour anion binding.

These substituent groups are discussed in detail in Reference 32.

25


The Ar^1 , Ar^2 and Ar^3 groups as defined in Reference 32 are also of interest as R^{N1} , R^{N2} and R^{N3} in the present invention.

Compounds of formula II

30 These compounds are either commercially available, or may be readily synthesised using known techniques.

Compounds of formula III

Compounds of formula III:




can be synthesised from compounds of Formula 1:




5

by methods known in the art. The method chosen will depend on the basicity of the amine of formula 1. Typically, the compound of formula 1 will be reacted with a base in organic solvent and then a compound of formula 2 added:




10

For example, some of the silylamines used in the examples below were prepared as follows from the free amine.

(i) TMSCl, NEt₃, CH₂Cl₂, 17h

(ii) a. n-BuLi, THF, -78°C, 2 h. b. TMSCL, rt, 17h

15 The silylamines where R^{N2} is sulfonyl were prepared as follows from a modified amine by heating with bis(trimethylsilyl)trifluoroacetamide (BSTFA).



The silylamines were purified by vacuum distillation. Once purified, their were handled under nitrogen at all times, and stored at -20°C.

5 If the desired compound of formula I is a tri-aryl amine, then the bi-aryl silyl amine of formula III, may itself be synthesised from a bi-aryl amine made by the method of the present invention.

10 *Further preferences*

The compounds of formula (I) may be oligomeric or polymeric in nature, as described in Reference 32. In particular, all of R^{N1}, R^{N2} and R^{N3} may be substituted C₅₋₂₀ aryl, preferably phenyl, with one of R^{N1}, R^{N2} and R^{N3} being a side chain group, and the other 15 two of R^{N1}, R^{N2} and R^{N3} being linked to form an oligomeric or polymeric backbone.

In some embodiments R^{N1} and R^{N2} are not linked by a single bond.

20 R^{N1}

R^{N1} is, in some embodiments, preferably optionally substituted C₅₋₇ aryl, more preferably optionally substituted phenyl.

25 R^{N2}

R^{N2} is preferably selected from optionally substituted C₅₋₂₀ aryl, optionally substituted C₅₋₂₀ heterocyclyl, and optionally substituted sulfonyl. If R^{N2} is a sulfonyl group, then the sulfonyl substituent is preferably optionally substituted C₁₋₇ alkyl.

30

R^{N2} is more preferably selected from optionally substituted C₅₋₂₀ aryl and optionally substituted C₅₋₂₀ heterocyclyl, with optionally substituted C₅₋₂₀ aryl (e.g. phenyl) being most preferred.

35

R^{N3}

R^{N3} is preferably selected from optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl. If R^{N3} is selected from C_{1-7} alkyl, it is preferably C_{1-4} alkyl, and most preferably methyl.

5 If R^{N3} is selected from C_{5-20} aryl, it is preferably C_{5-7} aryl, and most preferably phenyl.

 R^{N2} and R^{N3}

When R^{N2} and R^{N3} together with the nitrogen atom to which they are attached form optionally substituted nitrogen-containing C_{3-20} heterocyclyl or C_{5-20} heteroaryl, they preferably form optionally substituted nitrogen-containing C_{5-20} heterocyclyl or heteroaryl (e.g. pyrrolyl, indolyl).

15 R^1 , R^2 and R^3

R^1 , R^2 and R^3 are preferably independently selected from optionally substituted C_{1-7} alkyl, C_{5-20} aryl, C_{3-20} heterocyclyl and C_{1-7} alkoxy, or two of R^1 , R^2 and R^3 , together with the silicon atom to which they are attached, may form a silicon containing C_{5-7} heterocyclyl group. It is more preferred that R^1 , R^2 and R^3 are independently selected from optionally substituted C_{1-7} alkyl, C_{5-20} aryl and C_{3-20} heterocyclyl, with optionally substituted C_{1-7} alkyl being most preferred.


25 Examples of preferred $\text{SiR}^1\text{R}^2\text{R}^3$ groups include TMS, TES, TIPS, TDDMS, TBDPS and 1-methylsilacyclobutane.

Optional substituents

The optional substituents for R^{N1} , R^{N2} and R^{N3} when they are C_{5-20} aryl groups, for example phenyl, include, but are not limited to, C_{1-7} alkyl, C_{1-7} alkoxy and C_{1-7} alkyl ester, of which, in some embodiments, C_{1-7} alkoxy (e.g. OMe) and C_{1-7} alkyl ester (e.g. COOMe) are preferred.

ExamplesGeneral Method

Flame dried cesium carbonate (228 mg, 0.7 mmol, 1.4 eq), aryl bromide (0.5 mmol), palladium acetate (2.8 mg, 0.012 mmol, 2.5 mol%) and di-*tert*-butyl biphenylphosphine (7.5 mg, 0.025 mmol, 5 mol%) were placed in a 10 cm³ stainless steel cell and the cell sealed. The cell was evacuated and refilled with nitrogen (three cycles). The silylamine (1.2 eq) was injected through the inlet port and the cell connected to the CO₂ line and charged with CO₂ (99.9995% - further purified over an Oxisorb^{RTM} catalyst) to approximately 760 psi (volume ca. 1 cm³ liquid carbon dioxide). The cell was heated to 100°C and the pressure adjusted to the desired pressure by the addition of further CO₂. The reagents were maintained at this temperature and pressure for the desired time before the cell was allowed to cool to room temperature. The contents of the cell were vented into ethyl acetate (50 cm³), and once atmospheric pressure had been reached, the cell was opened and washed with further ethyl acetate (3 x 10 cm³). The combined organic fractions were filtered and concentrated *in vacuo* to furnish the crude material that was purified by flash column chromatography.

Example 1

The reaction was carried out as described in the general method.

- (a) R=COOMe, R'=COOMe, 3000 psi, 17 hours: Yield 84%
- (b) R=COOMe, R'=COOMe, 1800 psi, 17 hours: Yield 69%
- (c) R=COOMe, R'=OMe, 3000 psi, 17 hours: Yield 40%
- 30 (d) R=COOMe, R'=OMe, 1800 psi, 48 hours: Yield 77%
- (e) R=COOMe, R'=H, 3000 psi, 17 hours: Yield 28%
- (f) R=COOMe, R'=H, 1800 psi, 48 hours: Yield 76%
- (g) R=H, R'=COOMe, 1800 psi, 17 hours: Yield 77%


(h) R=H, R'=H, 1800 psi, 48 hours: Yield 55%
 (i) R=H, R'=OMe, 1800 psi, 48 hours: Yield 66%
 (j) R=OMe, R'=COOMe, 1800 psi, 17 hours: Yield 57%
 (k) R=OMe, R'=H, 1800 psi, 48 hours: Yield 25%
 5 (l) R=OMe, R'=OMe, 1800 psi, 48 hours: Yield 25%

As a comparison, the reaction was carried out with the same reagents in toluene, as follows. To an oven dried Schlenk tube under nitrogen was added cesium carbonate (228 mg, 0.7 mmol, 1.4 eq) and the cesium carbonate was flame dried under vacuum with stirring. Methyl bromobenzoate (108 mg, 0.5 mmol), palladium acetate (5.6 mg, 0.024 mmol, 5 mol%) and di-*tert*-butyl biphenylphosphine (15 mg, 0.05 mmol, 10 mol%) were added and the Schlenk tube sealed, and evacuated and refilled with nitrogen (3 cycles). A solution of the silylamine (1.2 eq) in dry toluene (1.5 cm³) was added and the reaction mixture heated at 100°C for the desired time. The reaction mixture was allowed to cool to room temperature. The mixture was filtered and concentrated *in vacuo* to furnish the crude material which was purified by flash column chromatography. The yields are shown in Table 1, with the time for each experiment in parentheses.


Table 1

	R=COOMe	R=H	R=OMe
R'=COOMe	66 (34h)	41 (17h)	63 (17h)
R'=H	65 (54h)	12 (17h)	8 (17h)
R'=OMe	72 (54h)	25 (17h)	7 (17h)

Example 2



The reaction was carried out as described in the general method,
with the R group and either the N-trimethylsilyl-pyrrole or
indole as shown in Table 3, with the yields expressed in %. The
reactions were carried out at ca. 1800 psi for 17 hours. The
catalyst ligand used was either:




wherein ligand A is that described in the general method.

Table 2

		Yield (%)	
Substrate	X	A	B
Pyrrole	COOMe	59	75
	H	11	46
	OMe	7	30
Indole	COOMe	70	88
	H	68	70
	OMe	25	50

Example 3



The reaction is carried out as described in the general method,
 5 wherein the starting material is added at the silylamine stage.
 An additive (1.2 eq) was sometimes added (see table 3) at the
 same time as the Cs_2CO_3 . The reaction was carried out at 1800
 psi for the length of time as shown in Table 3.

Table 3

R	Additive	Time (hours)	Yield (%)
*-C ₆ H ₄ -CH ₃	-	17	43
*-C ₆ H ₄ -CH ₃	-	41	61
*-C ₆ H ₄ -CH ₃	KF	41	57
-CH ₃	-	17	55
-CH ₃	-	41	28
-CH ₃	KF	17	72


10

As a comparison, the reaction was also carried out where the starting material did not bear the trimethyl silyl group, as shown in Table 4:

Table 4

R	Additive	Time (hours)	Yield (%)
*-C ₆ H ₄ -CH ₃	-	17	20
-CH ₃	-	17	22

15

Example 4

5 The reaction is carried out as described in the general method, and an additive (1.2 eq) was sometimes added (see table 5) at the same time as the Cs_2CO_3 . The reaction was carried out at 1800 psi for the length of time as shown in Table 5.

Table 5

R	R'	Additive	Time (hours)	Yield (%)
-CH ₃	COOMe	-	17	15
-CH ₃	COOMe	KF	17	56
-CH ₃	COOMe	KF	41	55

References

(all of which are herein incorporates by reference)

- (1) M. Stolka, J. F. Yanus, and D. M. Pai, *J. Phys. Chem.*, 1984, **88**, 4707-4714
- 5 (2) E. Ueta, H. Nakano, and Y. Shirota, *Chem. Lett.*, 1994, 2397.
- (3) Y. Kuwabara, H. Ogawa, H. Inada, N. Noma, and Y. Shirota, *Adv. Mater.*, 1994, **6**, 677.
- (4) M. Strukelj, R. H. Jordan, and A. Dodabalapur, *J. Am. Chem. Soc.*, 1996, **118**, 1213-1214.
- 10 (5) A. Kitani, M. Kaya, J. Yano, K. Yoshikawa, and K. Sasaki, *Synth. Met.*, 1987, **18**, 341-346.
- (6) F.-L. Lu, F. Wudl, M. Nowak, and A. J. Heeger, *J. Am. Chem. Soc.*, 1986, **108**, 8311-13.
- (7) A. G. MacDiarmid, J. C. Chiang, A. F. Richter, and A. J. Epstein, *Synth. Met.*, 1987, **18**, 285-290.
- 15 (8) A. G. MacDiarmid, and A. J. Epstein, *Faraday Discuss. Chem. Soc.*, 1989, **88**, 317-332.
- (9) A. G. MacDiarmid, and A. J. Epstein, *Science and Applications of Conducting Polymers*; Hilger: New York, 1991.
- 20 (10) A. Ray, A. F. Richter, D. L. Kershner, and A. J. Epstein, *Synth. Met.*, 1989, **29**, 141-150.
- (11) D. Vachon, R. O. Angus, Jr., F.-L. Lu, M. Nowak, Z. X. Liu, H. Schaffer, F. Wudl, and A.J. Heeger, *Synth. Met.*, 1987, **18**, 297-302.
- 25 (12) R. S. Oakes, A. A. Clifford, and C. M. Rayner, *J. Chem. Soc. Perkin Trans 1*, 2001, 917-941.
- (13) P. G. Jessop, and W. Leitner *Chemical Synthesis Using Supercritical Fluids*; Wiley-VCH: Weinheim, 1999.
- (14) A. I. Cooper, *Adv. Mater.*, 2001, **13**, 1111-1114.
- 30 (15) M. A. Carroll, and A. B. Holmes, *Chem. Commun.*, 1998, 1395-1396.
- (16) T. R. Early, R. S. Gordon, M. A. Carroll, A. B. Holmes, R. E. Shute, and I. F. McConvey, *Chem. Commun.*, 2001, 1966-1967.
- (17) R. S. Gordon, and A. B. Holmes, *Chem. Commun.*, 2002, 640-641.
- (18) S. V. Ley, C. Ramarao, R. S. Gordon, A. B. Holmes, A. J. Morrison, I. F. McConvey, I. M. Shirley, S. C. Smith, and M. D. Smith, *Chem. Commun.*, 2002, 1134-1135.
- 35 (19) N. Sundararajan, S. Yang, K. Ogino, S. Valiyaveettil, J. G. Wang, X. Y. Zhou, C. K. Ober, S. K. Obendorf, and R. D. Allen, *Chem. Mater.*, 2000, **12**, 41-48.

(20) Y. C. Bae, K. Douki, T. Y. Yu, J. Y. Dai, D. Schmaljohann, H. Koerner, C. K. Ober, and W. Conley, *Chem. Mater.*, 2002, 14, 1306-1313.

5 (21) J. M. D. E. Hoggan, R. G. Carbonell, *Polym. Prepr. Am. Chem. Soc. Div. PMSE, Part 2 Aug 22, 1999*, 218.

(22) S. L. Wells, and J. DeSimone, *Angew. Chem. Int. Ed. Engl.*, 2001, 40, 518-527.

10 (23) F. Gaspar, T. Lu, R. Santos, B. Al-Duri, A. B. Holmes, G. Leeke, W. T. S. Huck, C. K. Luscombe, and J. Seville, Patterned deposition using compressed carbon dioxide, 2003, EP 1 341 616.

(24) J. Lindley, *Tetrahedron*, 1984, 40, 1433-1456.

(25) H. L. Aalten, G. van Koten, and D. M. Grove, *Tetrahedron*, 1989, 45, 5565-5578.

15 (26) A. J. Paine, *J. Am. Chem. Soc.*, 1987, 109, 1496-1502.

(27) H. Weingarten, *J. Org. Chem.*, 1964, 29, 975-977.

(28) S. L. Buchwald, and A. S. Guram, Preparation of arylamines, 1994, US 5 576 460.

20 (29) J. P. Wolfe, S. Wagaw, J.-F. Marcoux, and S. L. Buchwald, *Acc. Chem. Res.*, 1998, 31, 805-818.

(30) J. F. Hartwig, *Angew. Chem. Int. Ed. Engl.*, 1998, 37, 2046-2047.

(31) B. Yang, and S. L. Buchwald, *J. Organometallic Chem.*, 1999, 576, 125-146; A. R. Muci and S. L. Buchwald in *Topics in Current Chemistry: Cross Coupling Reactions*, Vol. 219, Springer-Verlag, Berlin, 2002.

25 (32) A. B. Holmes, and T. Park, Electroactive polyarylamine-type compositions, 2002, WO 02/051958.

(33) C. Salvatore, Light emissive polymer blends and light emissive devices made from the same, 2003, EP 1 326 942.

(34) J. J. M. Halls, C. A. Walsh, N. C. Greenham, E. A. Marseglia, R. H. Friend, S. C. Moratti, and A. B. Holmes, *Nature*, 1995, 376, 498-500.

30 (35) A. Fürstner, L. Ackermann, K. Beck, H. Hori, D. Kock, K. Langermann, M. Liebl, C. Six, and W. Leitner, *J. Am. Chem. Soc.*, 2001, 123, 9000-9006.

(36) A.B. Holmes, R.S. Gordon, and T.R. Early, WO 03/009936.

35 (37) A. Baiker, *Chem. Rev.*, 1999, 99, 453-474 (p. 455)

(38) Shezad, N., Oakes, R. S., Clifford, A. A., and Rayner, C. M., *Chemical Industries (Dekker)* 2001, 82(Catalysis of Organic Reactions), 459-464

(39) N. Shezad, A.A. Clifford, and C.M. Rayner, *Green Chemistry* 2002, 4(1), 64-67

(40) WO96/01304

(41) WO95/22591

5 (42) WO94/20444

(43) WO94/06738

(44) EP 0 652 202

(45) US 6,156,933


10 (46) Nolan, *Ionic liquids as green solvents: progress and prospects*, ACS Symposium Series, 2003, 856, 323-341

(47) A. Deagostino, C. Prandi and P. Venurello, *Org. Lett.*, 2003, 5, 3815-3817

(48) *New Aspects in Phosphorus Chemistry II, Top. Curr. Chem.*, 2003, 223, 1-44

Claims


1. A method of synthesising a compound of formula I:



5 comprising the step of reacting a moiety of formula II:



with a moiety of formula III:



in compressed carbon dioxide in the presence of a transition metal catalyst and a base, wherein:

L is a labile leaving group;

R^{N1} is optionally substituted C_{5-20} aryl;

R^{N2} is selected from optionally substituted C_{5-20} aryl, optionally substituted C_{3-20} heterocyclyl, optionally substituted C_{3-7} alkyl, and optionally substituted sulfonyl;

R^{N3} is selected from H and optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl; or

R^{N2} and R^{N3} together with the nitrogen atom to which they are attached form optionally substituted nitrogen-containing C_{3-20} heterocyclyl or C_{5-20} heteroaryl; and

20 R^1 , R^2 and R^3 are independently selected from optionally substituted C_{1-7} alkyl, C_{5-20} aryl, C_{3-20} heterocyclyl, hydroxy, halo, amino and C_{1-7} alkoxy, or two of R^1 , R^2 and R^3 , together with the silicon atom to which they are attached, may form a silicon containing C_{5-7} heterocyclyl group.

2. A method according to claim 1, wherein the compressed carbon dioxide is supercritical carbon dioxide.

30 3. A method according to claim 1 or claim 2, wherein the transition metal catalyst is a palladium catalyst.

4. A method according to claim 3, wherein the palladium catalyst comprises one or more phosphine ligands.

5. A method according to any one of claims 1 to 4, wherein the base is selected from group 1 metal carbonate and tert-butoxy/phenoxy bases.

6. A method according to claim 6, wherein the base is Cs_2CO_3 .

10 7. A method according to any one of claims 1 to 6, wherein a fluoride source is present.

8. A method according to claim 7, wherein the fluoride source is selected from KF and CsF.

15 9. A method according to any one of claims 1 to 8, wherein the reaction is carried out at a temperature of between 20 and 200°C.

20 10. A method according to any one of claims 1 to 9, wherein the labile leaving group is selected from I, Br, Cl and OSO_2CF_3 .

25 11. A method according to any one of claims 1 to 10, wherein $\text{R}^{\text{N}2}$ is selected from optionally substituted C_{5-20} aryl, optionally substituted C_{5-20} heterocyclyl, and optionally substituted sulfonyl.

30 12. A method according to any one of claims 1 to 11, wherein $\text{R}^{\text{N}3}$ is selected from optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl.

35 13. A method according to any one of claims 1 to 12, wherein R^1 , R^2 and R^3 are independently selected from optionally substituted C_{1-7} alkyl, C_{5-20} aryl, C_{3-20} heterocyclyl and C_{1-7} alkoxy, or two of R^1 , R^2 and R^3 , together with the silicon atom

to which they are attached, may form a silicon containing C₅₋₇ heterocyclyl group.

